
- Volume 0 0
MYLAN BARRED FROM SELLING GENERIC TOPAMAX
A federal judge in NewJersey issued an injunctionpermanently barringMylan Pharmaceuticalsfrom selling generic topiramatetablets and capsulesin the United Statesbefore September 26,2008, the expiration dateof the patent for TOPAMAX(topiramate) heldby Ortho-McNeil NeurologicsInc. Mylan hadchallenged the validity ofthat patent and filed anabbreviated new drugapplication to market ageneric version of theepilepsy drug. The brandedmanufacturer counteredwith a patentinfringement complaintagainst Mylan and obtaineda preliminary injunctionagainst the genericfirm last fall.
Articles in this issue
about 19 years ago
can you READ these Rxs?about 19 years ago
compounding HOTLINEabout 19 years ago
Pseudoephedrine Logs Need Constant Tendingabout 19 years ago
Another Federal Court Rejects a Drug Importation Planabout 19 years ago
Home Infusion Therapy Gets Patients Out of the Hospitalabout 19 years ago
RESPy AWARD: Teamwork Is the Thread That Bindsabout 19 years ago
Child-resistant Does Not Mean Childproofabout 19 years ago
ccpa SPEAKS OUT: CCPA Works to Improve Medicare Part Dabout 19 years ago
Genetic Testing: Remarkable Resource or Invasion of Privacy?about 19 years ago
case STUDIES







































































































































